Exco InTouch Unveils Exco Valued Partner Network at the Partnershi?ps in Clinical Trials Congress
![](/46/pdcnewsitem/03/32/07/RJv8m8mI1Q2MWP9.png)
Exco InTouch, the leading provider of patient engagement and data capture solutions for clinical research and healthcare providers, will unveil the Exco Valued Partner Network at The Partnerships in Clinical Trials Congress taking place in Las Vegas 30 March–2 April 2014. The company, which already services all of the world’s top ten pharmaceutical companies (ranked by 2013 revenues), will now highlight the competitive advantages, benefits and unique factors that mark out its novel Exco Valued Partner Network. Exco InTouch, which will be exhibiting at stand 416, will also demonstrate its approach to BYOD (bring your own device) and more broadly to data capture and patient engagement services across clinical and late phase programs.
The Exco Valued Partner Network, has been created to enable Exco InTouch’s extensive pool of partners to benefit from collaborative activities and to experience the full range of services and capabilities offered first hand. Unique services, available to Exco InTouch partners, include the Exco Partner Cloud, a secure web portal that supports partner business development teams. The cloud enables partners to access tailored demonstrations, videos, case studies and co-branded materials, as well as providing information on their experience working together.
Other notable benefits of the network include innovation in the use of every day technologies, rapid access to patient centric solutions, a modular approach to system delivery, a BYOD cost saving model and enabling incorporation of ePRO capture into clinical studies. In addition, the network provides valuable partner programme benefits that range across governance, with executive team leaders assigned to champion each individual partnership, preferred flexible pricing, master services agreements, operational, marketing and strategic business support.
Tim Davis, CEO and co-founder of Exco InTouch commented: “We are delighted to have the opportunity to highlight the extensive benefits and advantages that our partners can enjoy when they join our Exco Valued Partner Network. We are committed to strong partnerships with clients, seeing this as mutually beneficial to all concerned. We are always on the look-out for ways to optimise the value added services that we provide to customers in the field of data capture and patient engagement. Our partnership programs form an essential and integral component to our strategy for continuing to achieve this important objective.”
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance